Feasibility of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer and atrial fibrillation

BACKGROUND: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a significant improvement in the treatment of patients with metastatic castration-resistant prostate cancer. The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, cou...

全面介紹

Na minha lista:
書目詳細資料
發表在:Prostate Int
Main Authors: Rauch, Simon, Fong, Dominic, Morra, Elisa, Maines, Francesca, Caffo, Orazio, Spizzo, Gilbert
格式: Artigo
語言:Inglês
出版: Asian Pacific Prostate Society 2016
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4916059/
https://ncbi.nlm.nih.gov/pubmed/27358844
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.prnil.2016.02.002
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍